CYP3A5*3 Polymorphism and Its Clinical Implications and Pharmacokinetic Role

다국어 초록 (Multilingual Abstract)

The cytochrome P450 (CYP) 3A subfamily is estimated to participate in the biotransformation of 50% of the currently prescribed drugs. Four members of the CYP3A subfamily have been identified in humans: CYP3A4, CYP3A5, CYP3A7, and CYP3A43. Initial data suggested that CYP3A5 accounts for only a small proportion of the total hepatic CYP3A in about 20% of samples, but it was later revealed that CYP3A5 represents more than 50% of the total CYP3A amount in some individuals.
Several genetic variants have been described for the CYP3A5 gene, of which the CYP3A5*3 allele (gA6986G), the most common form and leading to the loss of CYP3A5 activity, has been extensively investigated in the aspect of pharmacokinetics and disease risk. This review summarized the molecular characteristics of the CYP3A5 gene, and discusses the association of the CYP3A5*3 polymorphism with disease risks such as cancer and hypertension, along with its role in the pharmacokinetics of CYP3A substrates.

참고문헌 (Reference)

1 Paulussen A, "Two linked mutations in transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity in humans" 10 : 415-424, 2000

2 Hustert E, "The genetic determinants of the CYP3A5 polymorphism" 11 : 773-779, 2001

3 Roberts-Thomson SJ, "The catalytic activity of four expressed human cytochrome P450s towards benzo[a]pyrene and the isomers of its proximate carcinogen" 192 : 1373-1379, 1993

4 Wrighton SA, "Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3)" 38 : 207-213, 1990

5 Willrich MA, "Statin regulation of CYP3A4 and CYP3A5 expression" 10 : 1017-1024, 2009

6 Jounaïdi Y, "Sequence of the 5'-flanking region of CYP3A5: comparative analysis with CYP3A4 and CYP3A7" 205 : 1741-1747, 1994

7 Kuehl P1, "Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression" 27 : 383-391, 2001

8 Shimada T, "Roles of individual human cytochrome P-450 enzymes in the bioactivation of benzo(a)pyrene, 7,8-dihydroxy-7,8-dihydrobenzo(a)pyrene, and other dihydrodiol derivatives of polycyclic aromatic hydrocarbons" 49 : 6304-6312, 1989

9 Wang K, "Retinoids induce cytochrome P450 3A4 through RXR/VDR-mediated pathway" 75 : 2204-2213, 2008

10 Ghosh S, "Renal corticosterone 6 beta-hydroxylase in the spontaneously hypertensive rat" 1182 : 152-156, 1993

11 Liu TC, "Polymorphism analysis of CYP3A5 in myeloid leukemia" 9 : 327-329, 2002

12 Evans WE, "Pharmacogenomics: translating functional genomics into rational therapeutics" 286 : 487-491, 1999

13 Lakhman SS, "Pharmacogenomics of CYP3A: considerations for HIV treatment" 10 : 1323-1339, 2009

14 Nelson DR, "P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature" 6 : 1-42, 1996

15 Le Moual N, "Occupational exposures estimated by means of job exposure matrices in relation to lung function in the PAARC survey" 52 : 634-643, 1995

16 Fukuen S, "Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population" 12 : 331-334, 2002

17 Jia Y, "No association between polymorphisms in three genes of cytochrome p450 family and paranoid schizophrenia in northern Chinese Han population" 19 : 374-376, 2004

18 Burk O, "Molecular mechanisms of polymorphic CYP3A7 expression in adult human liver and intestine" 277 : 24280-24288, 2002

19 Shimada T, "Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians" 270 : 414-423, 1994

20 Dally H, "Genotype relationships in the CYP3A locus in Caucasians" 207 : 95-99, 2004

21 Gellner K, "Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene" 11 : 111-121, 2001

22 Gervasini G, "Genetic variability in CYP3A4 and CYP3A5 in primary liver, gastric and colorectal cancer patients" 7 : 118-, 2007

23 Chou FC, "Genetic polymorphism of cytochrome P450 3A5 in Chinese" 29 : 1205-1209, 2001

24 Lee SJ, "Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups" 13 : 461-472, 2003

25 Lamba JK, "Genetic contribution to variable human CYP3A-mediated metabolism" 54 : 1271-1294, 2002

26 Lee SJ, "Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests" 6 : 357-371, 2005

27 Feng WX, "Functional polymorphisms in CYP2C19 & CYP3A5 genes associated with decreased susceptibility for paediatric tuberculosis" 135 : 642-649, 2012

28 Piipari R, "Expression of CYP1A1, CYP1B1 and CYP3A, and polycyclic aromatic hydrocarbon-DNA adduct formation in bronchoalveolar macrophages of smokers and non-smokers" 86 : 610-616, 2000

29 Utecht KN, "Effects of genetic polymorphisms on the pharmacokinetics of calcineurin inhibitors" 63 : 2340-2348, 2006

30 Kang RH, "Effects of CYP2D6 and CYP3A5 genotypes on the plasma concentrations of risperidone and 9-hydroxyrisperidone in Korean schizophrenic patients" 29 : 272-277, 2009

31 Kim KA, "Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects" 47 : 87-93, 2007

32 Kim KA, "Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects" 80 : 646-656, 2006

33 Park JY, "Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects" 79 : 590-599, 2006

34 Park PW, "Effect of CYP3A5*3 genotype on serum carbamazepine concentrations at steady-state in Korean epileptic patients" 34 : 569-574, 2009

35 Jounaïdi Y, "Detection of CYP3A5 allelic variant: a candidate for the polymorphic expression of the protein?" 221 : 466-470, 1996

36 Watlington CO, "Corticosterone 6 beta-hydroxylation correlates with blood pressure in spontaneously hypertensive rats" 262 : F927-F931, 1992

37 Westlind A, "Cloning and tissue distribution of a novel human cytochrome p450 of the CYP3A subfamily, CYP3A43" 281 : 1349-1355, 2001

38 Wojnowski L, "Clinical implications of CYP3A polymorphisms" 2 : 171-182, 2006

39 Wang BS, "CYP3A5*3 polymorphism and cancer risk: a meta-analysis and meta-regression" 34 : 2357-2366, 2013

40 Sinues B, "CYP3A5*3 and CYP3A4*1B allele distribution and genotype combinations:differences between Spaniards and Central Americans" 29 : 412-416, 2007

41 Balram C, "CYP3A5*3 and *6 single nucleotide polymorphisms in three distinct Asian populations" 59 : 123-126, 2003

42 Zhang YP, "CYP3A5 polymorphism, amlodipine and hypertension" 28 : 145-149, 2014

43 Dandara C, "CYP3A5 genotypes and risk of oesophageal cancer in two South African populations" 225 : 275-282, 2005

44 Roy JN, "CYP3A5 genetic polymorphisms in different ethnic populations" 33 : 884-887, 2005

45 Plummer SJ, "CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer" 12 : 928-932, 2003

46 Kristiansen W, "CYP1A1, CYP3A5 and CYP3A7 polymorphisms and testicular cancer susceptibility" 34 : 77-83, 2011

47 Kaur-Knudsen D, "CHRNA3 and CYP3A5* 3 genotype, lung function and chronic obstructive pulmonary disease in the general population" 24 : 220-229, 2014

48 Rao DN, "Association of CYP3A5*3 polymorphism with development of acute leukemia" 17 : 175-178, 2011

49 Islam MS, "Association of CYP3A4, CYP3A5 polymorphisms with lung cancer risk in Bangladeshi population" 35 : 1671-1678, 2014

50 Rais N, "Association between urinary 6b-hydroxycortisol/cortisol ratio and CYP3A5 genotypes in a normotensive population" 5 : 527-532, 2013

51 Ho H, "Association between the CYP3A5 genotype and blood pressure" 45 : 294-298, 2005

52 Cui JS, "Antihypertensive treatments obscure familial contributions to blood pressure variation" 41 : 207-210, 2003

53 Du J, "A case-control association study between the CYP3A4 and CYP3A5 genes and schizophrenia in the Chinese Han population" 33 : 1200-1204, 2009